NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,190+0.67%BTC$85,975−0.58%VIX16.23+6.01%live tape · as of 11:17 UTC
The Screen · Healthcare · Medical Devices
Picard Medical Inc
PMI · NYSE AMERICAN · USD · Market cap $12M · 75 employees
Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price4.21 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Distribution4.21+0.0% to today
2026-07-02Read Markup0.18+2,252.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Picard Medical Inc holds its Accumulation at $4.21. The statistical read favours the sellers, held for 1 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 1 days
Price at the screen
$4.21
Valuation
N/A trailing · -1.13 forward price to earnings
Values screen
PASS· score 70.0
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.93%
Below 33%
Interest-bearing debt is just 30.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
35.81%
Below 49%
Money owed to the company is 35.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Picard Medical clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PMI trades on NYSE AMERICAN. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Distribution · changed$4.21-8.1%Entry 6
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-09-09Markup$4.58+3,166.8%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3166.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-08-08Markup$0.14-21.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 21.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-18Markup$0.18+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 14%.
2026-07-03Markup$0.18+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$0.18Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.